About lipella pharmaceuticals inc - LIPO
Lipella Pharmaceuticals, Inc. develops and commercializes lipid-based therapies for common bladder syndromes. It offers LP-08 which consists of Sphingomyelin Phospholipid bilayers separated by aqueous compartments, LP-09, a liposomal formulation of Botulinum toxin, and LP-10, a proprietary liposomal formulation of Tacrolimus, a potent immunosuppressant and anti-inflammatory agent. The company was founded by Jonathan Kaufman and Michael Chancellor on February 15, 2005 and is headquartered in Pittsburgh, PA.
LIPO At a Glance
Lipella Pharmaceuticals, Inc.
7800 Susquehanna Street
Pittsburgh, Pennsylvania 15208
| Phone | 1-412-901-0315 | Revenue | 536.36K | |
| Industry | Pharmaceuticals: Major | Net Income | -5,016,264.00 | |
| Sector | Health Technology | 2024 Sales Growth | 19.292% | |
| Fiscal Year-end | 12 / 2025 | Employees | 7 | |
| View SEC Filings |
LIPO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 5.961 |
| Price to Book Ratio | 1.921 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.209 |
| Enterprise Value to Sales | 1.976 |
| Total Debt to Enterprise Value | 0.045 |
LIPO Efficiency
| Revenue/Employee | 76,622.429 |
| Income Per Employee | -716,609.143 |
| Receivables Turnover | 6.331 |
| Total Asset Turnover | 0.172 |
LIPO Liquidity
| Current Ratio | 3.469 |
| Quick Ratio | 3.469 |
| Cash Ratio | 2.896 |
LIPO Profitability
| Gross Margin | 99.462 |
| Operating Margin | -947.231 |
| Pretax Margin | -935.247 |
| Net Margin | -935.247 |
| Return on Assets | -160.494 |
| Return on Equity | -198.119 |
| Return on Total Capital | -255.014 |
| Return on Invested Capital | -196.282 |
LIPO Capital Structure
| Total Debt to Total Equity | 2.48 |
| Total Debt to Total Capital | 2.42 |
| Total Debt to Total Assets | 1.78 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |